ImmunityBio IBRX
NASDAQ IBRX
$8.11 -0.07 (-0.92%)
As of: Sep 4, 2026 · 12:48 PM EDT

ImmunityBio (IBRX) Non Operating Interest Expenses (2016 - 2026)

Analysis

ImmunityBio (IBRX) Non Operating Interest Expenses (2016 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non Operating Interest Expenses (Qtr)
1 Vertex Pharmaceuticals 139.76 Bn 131.91 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 85.72 Bn 77.72 Bn 3.93 Bn 11.00 Mn
3 Argenx Se 63.56 Bn 58.38 Bn 1.37 Bn -1.00 Mn
4 Moderna 57.87 Bn 52.73 Bn 52.00 Mn -
5 Revolution Medicines 44.06 Bn 44.06 Bn - 23.78 Mn
6 BeOne Medicines 40.08 Bn 34.98 Bn 1.53 Bn 39.74 Mn
7 Alnylam Pharmaceuticals 35.50 Bn 32.20 Bn 992.69 Mn 82.05 Mn
8 Royalty Pharma 28.54 Bn 27.70 Bn - 93.62 Mn
9 Insmed 27.49 Bn 26.33 Bn 358.27 Mn 20.27 Mn
10 ImmunityBio 8.53 Bn 8.17 Bn 50.94 Mn 14.05 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 14.05 Mn
Mar 31, 2026 14.59 Mn
Dec 31, 2025 14.84 Mn
Sep 30, 2025 15.26 Mn
Jun 30, 2025 15.47 Mn
Mar 31, 2025 15.31 Mn
Dec 31, 2024 26.02 Mn
Sep 30, 2024 29.32 Mn
Jun 30, 2024 29.79 Mn
Mar 31, 2024 29.46 Mn
Dec 31, 2023 400,000.00
Sep 30, 2023 35.02 Mn
Jun 30, 2023 32.24 Mn
Mar 31, 2023 29.82 Mn
Dec 31, 2022 28.56 Mn
Sep 30, 2022 16.76 Mn
Jun 30, 2022 9.70 Mn
Mar 31, 2022 8.49 Mn
Dec 31, 2021 4.49 Mn
Sep 30, 2021 3.61 Mn